Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of ...

SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] The Subject Expert Commit ...

Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...

At the forefront is its blockbuster immuno-oncology drug, Opdivo, complemented by heavy hitters like Revlimid, Pomalyst, ...

Perioperative chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) shows promising long-term benefits with ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Opdivo plus Yervoy for the ...

Patients with metastatic non-small cell lung cancer, even those with brain metastases, experienced improved longer-term ...